...
首页> 外文期刊>Clinical therapeutics >Effects of low doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol levels in patients with hypercholesterolemia.
【24h】

Effects of low doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol levels in patients with hypercholesterolemia.

机译:小剂量辛伐他汀和阿托伐他汀对高胆固醇血症患者高密度脂蛋白胆固醇水平的影响。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: Simvastatin 40 to 80 mg/d has been found to increase high-density lipoprotein cholesterol (HDL-C) levels significantly more than atorvastatin at equipotent doses (ie, 20-80 mg/d). Data on the effects of lower doses of the 2 drugs on HDL-C levels are conflicting. OBJECTIVE: The purpose of this study was to investigate the effects of simvastatin 20 mg/d and atorvastatin 10 mg/d on HDL-C levels in patients with hypercholesterolemia. METHODS: Patients with primary hypercholesterolemia (total cholesterol [TC] >250 mg/dL) who were not taking any lipid-lowering agents and who were following a low-fat diet were randomized to receive 1 of 2 treatments: simvastatin 20 mg/d or atorvastatin 10 mg/d. Serum TC, triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and HDL-C levels were measured using standard methods after 2 months of therapy. In a secondary analysis, lipids and lipoprotein cholesterol were measured after 1 year in patients who continued treatment. RESULTS: Of the 240 patients enrolled (108 men and 132 women; age range, 23-77 years, mean [SEM] 56.7 [0.69]), 235 completed the study. After 2 months of therapy, TC, LDL-C, and serum TG levels decreased significantly versus baseline in both groups (P < 0.001), with no significant differences between treatment groups. HDL-C levels increased by 9.0% (P [ 0.001 vs baseline) in the simvastatin group and by 4.3% (P < 0.02) in the atorvastatin group. The difference between the 2 groups in the percentage increase in HDL-C was statistically significant (P < 0.05). In 113 patients who continued treatment, HDL-C levels at 1 year were still significantly higher than baseline levels in the simvastatin group (6.3%, P = 0.034), but not in the atorvastatin group (2.8%, P = 0.587). CONCLUSIONS: The findings from this study suggest that the HDL-C-increasing effect of simvastatin 20 mg is significantly greater than that of atorvastatin 10 mg. Since increasing HDL-C levels is thought to lower the risk for atherosclerosis and coronary heart disease, these results warrant further investigation.
机译:背景:在等效剂量(即20-80 mg / d)下,辛伐他汀40至80 mg / d被发现比阿托伐他汀对高密度脂蛋白胆固醇(HDL-C)水平的增加明显多。关于低剂量两种药物对HDL-C水平的影响的数据相互矛盾。目的:研究辛伐他汀20 mg / d和阿托伐他汀10 mg / d对高胆固醇血症患者HDL-C水平的影响。方法:原发性高胆固醇血症(总胆固醇[TC]> 250 mg / dL),不服用任何降脂药,低脂饮食的患者随机接受2种治疗方法之一:辛伐他汀20 mg / d或阿托伐他汀10 mg / d。治疗2个月后,使用标准方法测量血清TC,甘油三酸酯(TG),低密度脂蛋白胆固醇(LDL-C)和HDL-C水平。在二级分析中,对继续治疗的患者在1年后测量了脂质和脂蛋白胆固醇。结果:在240名患者中(108名男性和132名女性;年龄范围23-77岁,平均[SEM] 56.7 [0.69]),有235名患者完成了研究。在治疗2个月后,两组的TC,LDL-C和血清TG水平均显着下降(P <0.001),治疗组之间无显着差异。辛伐他汀组的HDL-C水平增加了9.0%(相对于基线,P [0.001),阿托伐他汀组的HDL-C水平增加了4.3%(P <0.02)。两组之间HDL-C百分比增加的差异具有统计学意义(P <0.05)。在113名继续接受治疗的患者中,辛伐他汀组1年的HDL-C水平仍显着高于基线水平(6.3%,P = 0.034),但阿托伐他汀组未升高(2.8%,P = 0.587)。结论:这项研究的结果表明辛伐他汀20 mg的HDL-C增强作用明显大于阿托伐他汀10 mg。由于人们认为增加HDL-C水平可降低动脉粥样硬化和冠心病的风险,因此这些结果值得进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号